Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by AVROBIO, Inc.

< Previous 1 2 Next >
AVROBIO Announces Preclinical Gene Therapy Data for Pompe Disease at American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
From AVROBIO, Inc.
Via Business Wire
Tickers AVRO
AVROBIO Reports Positive Data From Phase 1/2 Clinical Trial of Investigational Gene Therapy for Cystinosis, Including New Interim Data on Neurocognitive Measures
From AVROBIO, Inc.
Via Business Wire
Tickers AVRO
AVROBIO to Present at the H.C. Wainwright Global Investment Conference
From AVROBIO, Inc.
Via Business Wire
Tickers AVRO
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From AVROBIO, Inc.
Via Business Wire
Tickers AVRO
AVROBIO to Present New Clinical and Preclinical Data at the ASGCT 25th Annual Meeting
From AVROBIO, Inc.
Via Business Wire
Tickers AVRO
AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From AVROBIO, Inc.
Via Business Wire
Tickers AVRO
AVROBIO to Present at the 21st Annual Needham Virtual Healthcare Conference
From AVROBIO, Inc.
Via Business Wire
Tickers AVRO
AVROBIO Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides Business Update
From AVROBIO, Inc.
Via Business Wire
Tickers AVRO
AVROBIO Reports Interim Data from Phase 1/2 Clinical Trial of Investigational Gene Therapy for Cystinosis
From AVROBIO, Inc.
Via Business Wire
Tickers AVRO
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From AVROBIO, Inc.
Via Business Wire
Tickers AVRO
AVROBIO Announces the Appointment of Sean O’Bryan as Chief Regulatory Officer
From AVROBIO, Inc.
Via Business Wire
Tickers AVRO
AVROBIO to Present at Cowen’s 2nd Annual Genetic Medicines Summit
From AVROBIO, Inc.
Via Business Wire
Tickers AVRO
AVROBIO to Present New Data from Phase 1/2 Clinical Trial in Cystinosis at WORLDSymposium™ 2022
From AVROBIO, Inc.
Via Business Wire
Tickers AVRO
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From AVROBIO, Inc.
Via Business Wire
Tickers AVRO
AVROBIO Reprioritizes Pipeline Programs
From AVROBIO, Inc.
Via Business Wire
Tickers AVRO
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From AVROBIO, Inc.
Via Business Wire
Tickers AVRO
AVROBIO Presents Clinician Experience with FAB-GT Clinical Trial and Updated Safety Data for Investigational Gene Therapies in Fabry Disease and Gaucher Disease Type 1
From AVROBIO, Inc.
Via Business Wire
Tickers AVRO
AVROBIO to Present at Two Upcoming Investor Conferences in November
From AVROBIO, Inc.
Via Business Wire
Tickers AVRO
AVROBIO to Present Clinical and Preclinical Data at the 14th ICIEM Conference
From AVROBIO, Inc.
Via Business Wire
Tickers AVRO
AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From AVROBIO, Inc.
Via Business Wire
Tickers AVRO
AVROBIO Reports Third Quarter 2021 Financial Results and Provides Business Update
From AVROBIO, Inc.
Via Business Wire
Tickers AVRO
AVROBIO Receives Rare Pediatric Disease Designation from the U.S. FDA for AVR-RD-05, a Gene Therapy for Mucopolysaccharidosis Type II (MPSII) or Hunter Syndrome
From AVROBIO, Inc.
Via Business Wire
Tickers AVRO
AVROBIO Announces the Appointment of Essra Ridha, M.D., MRCP, FFPM, as Chief Medical Officer
From AVROBIO, Inc.
Via Business Wire
Tickers AVRO
AVROBIO to Present at the Jefferies Virtual Gene Therapy/Editing Summit
From AVROBIO, Inc.
Via Business Wire
Tickers AVRO
AVROBIO Reports New Interim Safety Data Across Investigational Gene Therapies for Fabry and Gaucher Disease Type 1
From AVROBIO, Inc.
Via Business Wire
Tickers AVRO
AVROBIO to Present New Clinical and Preclinical Data Across Multiple Programs at the ESGCT 28th Annual Congress
From AVROBIO, Inc.
Via Business Wire
Tickers AVRO
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From AVROBIO, Inc.
Via Business Wire
Tickers AVRO
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From AVROBIO, Inc.
Via Business Wire
Tickers AVRO
AVROBIO to Participate at Four Upcoming Investor Conferences
From AVROBIO, Inc.
Via Business Wire
Tickers AVRO
AVROBIO Reports Second Quarter 2021 Financial Results and Provides Business Update
From AVROBIO, Inc.
Via Business Wire
Tickers AVRO
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.